Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
American Journal of Therapeutics|May 13, 2009
Pharmacokinetics of laropiprant and glucuronide metabolite in patients with severe renal insufficiencyMark Stroh, Larissa Wenning, Wen-Lin Luo, et al.Nature Medicine|May 10, 2005
Quantum dots spectrally distinguish multiple species within the tumor milieu in vivoMark Stroh, John P Zimmer, Dan G Duda, et al.Cancer Chemotherapy and Pharmacology|February 1, 2012
The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimusMark Stroh, John Palcza, Jacqueline McCrea, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021
Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor MalignanciesMelissa Johnson, Anthony El-Khoueiry, Navid Hafez, et al.Journal for Immunotherapy of Cancer|July 24, 2021
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding studyRachel E Sanborn, Omid Hamid, Elisabeth Ge de Vries, et al.Journal of Clinical Pharmacology|May 16, 2014
Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: model prediction and clinical confirmationMark Stroh, Jennifer Talaty, Punam Sandhu, et al.Cancer Chemotherapy and Pharmacology|August 11, 2012
A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancerRichard M Lush, Amita Patnaik, Daniel Sullivan, et al.Journal of Clinical Pharmacology|June 4, 2009
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's diseaseCarol Addy, Chris Assaid, David Hreniuk, et al.Molecular Pharmacology|March 24, 2011
RNA-induced silencing complex-bound small interfering RNA is a determinant of RNA interference-mediated gene silencing in miceJie Wei, Jeffrey Jones, Jing Kang, et al.The Oncologist|March 10, 2017
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal CancerRocío García-Carbonero, Eric van Cutsem, Fernando Rivera, et al.Pageof 4